



RECEIVED
PATENT
MAY 13 2002
Docket No: DIE01-NP002
TECH CENTER 1600/2900

#6
Mw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Dietzschold**

Group Art Unit: **1635**

Examiner: **Tara Washington**

Serial No.: **09/924,112**

Filed: **August 7, 2001**

**TRANSMITTAL OF INFORMATION
DISCLOSURE STATEMENT WITHIN
THREE MONTHS OF FILING OR
BEFORE MAILING OF FIRST OFFICE
ACTION (37 CFR 1.97(b))**

Title: **"Rhabdovirus-based Vectors to
Express High Levels of Functional :
Human Antibodies"**

Commissioner of Patents and Trademarks
Washington, D.C. 20231

Dear Sir:


The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or before the mailing date of a first Office Action on the merits, whichever event occurs last.

Respectfully submitted,

Date: May 7, 2002

Registration No: 45,461


Phone No: (215) 503-2386


Janet B. Smith, Ph.D.
Patent Agent
Thomas Jefferson University
1020 Walnut Street - 6th Floor
Philadelphia, PA 19103-2793

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited on the date shown below with the United States Postal Service as first class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Date: May 7, 2002


Janyce Lingo

Docket No.: D1001-0002

RECEIVED

MAY 13 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Dietzschold

Group Art Unit: 1635

Examiner: Tara Washington

Serial No.: 09/924,112

INFORMATION

Filed: August 7, 2001

DISCLOSURE

STATEMENT

Title: "Rhabdovirus-based Vectors
to Express High Levels of
Functional Human
Antibodies"

Commissioner of Patents and Trademarks
Washington, D.C. 20231

Dear Sir:

List Of Sections Forming Part Of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. Preliminary Statements
2. Form PTO - 1449 (Modified)
3. Copies of Listed Information Items Accompanying This Statement
4. Identification of Person(s) Making This Information Disclosure Statement

Section 1. Preliminary Statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.56(g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

05/10/2002 HNDDR1 00000115 500491 09924112

01 FC:126 180.00 CH



PATENT
RECEIVED


MAY 13 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited on the date shown below with the United States Postal Service as first class mail in an envelope addressed to: Box Issue Fee, Assistant Commissioner for Patents, Washington, D.C. 20231.

Date:



Janyce Lingo

RECEIVED


Sheet 1 of 2

MAY 13 2002

Form PTO - 1449
(Modified)U.S. Department of Commerce
Patent and Trademark Office

Docket No: DIE01-NP002
 Serial No.: 09/924, 112
 Applicant: DIETZCHOLD, Barbara
 Filing Date: August 7, 2001
 Art No. 1635
 Examiner Tara Washington

Information Disclosure
 Statement by Applicant
 (use several Sheets if necessary)



TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Exmr Initial	Patent Number	Issue Date	Patentee	Class	Sub- Class	Filing Date If Appropriate

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Exmr Initial	Document Number	Publn Date*	Country or Patent Office	Class	Sub- Class	Translation? Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication**)

AA	Whitelam, G., Cockburn, W., & Owen, M. "Antibody Production in Transgenic Plants." <i>Biochemical Society Transactions</i> 22: 940-949, 1994.
AB	Habel, K. "Isogenic Versus Allogeneic Antiserum in the Prophylaxis of Experimental Rabies." <i>Bulletin of the World Health Organization</i> 38: 383-387, 1968.
AC	Schnell, M., Mebatsion, T., & Conzelmann, K. "Infectious Rabies Viruses From Cloned cDNA." <i>The EMBO Journal</i> 13 (18): 4195-4203, 1994.
AD	Arakawa, F., Haruno, M., Kuroki, M., Kanda, H., Watanabe, T., Misumi, Y., & Matsuoka, Y. "Construction and Expression of Two Mouse-human Chimeric Antibodies with High Specificity and Affinity for Carcinoembryonic Antigen." <i>Hybridoma</i> 12 (4): 365-379, 1993.
AE	Ueki, Y., Goldfarb, I., Harindranath, N., Gore, M., Koprowski, H., Notkins, A., & Casali, P. "Clonal analysis of a Human Antibody Response." <i>The Journal of Experimental Medicine</i> 171: 19-34, 1990.
AF	Dietzschold, B., Gore, M., Casali, P., Ueki, Y., Rupprecht, C., Notkins, A., & Koprowski, H. "Biological characterization of Human Monoclonal Antibodies to Rabies Virus." <i>Journal of Virology</i> 64 (6): 3087-3090, 1990.
AG	Beidler, C., Ludwig, J., Cardenas, J., Phelps, J., Papworth, C., Melcher, E., Sierzege, M., Myers, L., Unger, B., Fisher, M., David, G., & Johnson, M. "Cloning and High Level Expression of a Chimeric Antibody with Specificity for Human Carcinoembryonic Antigen." <i>Journal of Immunology</i> 141 (11) 4053-4060, 1988.
AH	Champion, J., Kean, R., Rupprecht, C., Notkins, A., Koprowski, H., Dietzschold, B., & Hooper, D. "The Development of Monoclonal Human Rabies Virus-neutralizing Antibodies as a Substitute for Pooled Human Immune Globulin in the Prophylactic Treatment of Rabies Virus Exposure." <i>Journal of Immunology</i> 235: 81-90, 2000.
AI	Buchholz, U., Finke, S., & Conzelmann, K. "Generation of Bovine Respiratory Syncytial Virus (BRSV) from cDNA: BRSV NS2 is Not Essential for Virus Replication in Tissue Culture, and the Human RSV Leader Region Acts as a Functional BRSV Genome Promoter." <i>Journal of Virology</i> 73 (1): 251-259, 1999.

Examiner	Date Considered

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO - 1449)

- * Use publication date indicated on the patent or published application. 37 CFR 1.98(b).
 ** The place or publication refers to the name of the journal, magazine or other publication in which the article was published. Notice of January 9, 1992, 1135 O.G. 13 to 25 at 20.

RECEIVED
MAY 12 3 2002
Sheet 2 of 2
CENTER 1600/2900

A circular black ink stamp from the Canadian Intellectual Property Office (CIPO). The text "CIPO" is at the top, "MAY 07 2002" is in the center, and "PATENT & TRADEMARK OFFICE" is at the bottom. The stamp is slightly tilted.

Docket No:	DIE01-NP002
Serial No.:	09/924, 112
Applicant:	DIETZSCHOLD
Filing Date:	August 7, 2001
Art No.	1635
Examiner	Tara Washington

TECH CENTER 1600/2900

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)**

Examiner	Date Considered

(Form PTO – 1449)

- * Use publication date indicated on the patent or published application. 37 CFR 1.98(b).
 ** The place or publication refers to the name of the journal, magazine or other publication in which the article was published. Notice of January 9, 1992, 1135 O.G. 13 to 25 at 20.